Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

December 12, 2019

Study Completion Date

February 20, 2020

Conditions
Dry EyeGraft-versus-host-diseaseOcular Discomfort
Interventions
BIOLOGICAL

CAM-101 10%

fibrinogen-depleted human platelet lysate

BIOLOGICAL

Vehicle Control

PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop

BIOLOGICAL

CAM-101 30%

fibrinogen-depleted human platelet lysate

Trial Locations (6)

27710

Duke University Eye Center, Durham

48105

University of Michigan - Kellogg Clinical Research Center, Ann Arbor

55455

University of Minnesota, Minneapolis

94303

Byers Eye Institute of Stanford University, Palo Alto

97239

Oregon Health Sciences University - Casey Eye Institute, Portland

02114

Massachusetts Eye and Ear Infirmary, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Massachusetts Eye and Ear Infirmary

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

University of Michigan

OTHER

collaborator

Duke University

OTHER

collaborator

Stanford University

OTHER

collaborator

University of Minnesota

OTHER

lead

Cambium Bio Limited

INDUSTRY

NCT03414645 - Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease | Biotech Hunter | Biotech Hunter